Skin Reactivity during Immunotherapy

Image

Skin Reactivity during Immunotherapy

Parallel line bioassay (PLBA) has been acknowledged to be the gold standard for estimation of changes in reactivity, e.g., in RAST and ELISA inhibition tests
correlations between two simple methods for evaluation of changes in skin prick test (δSPT), using the slope of the allergen dose response (drra) in relation to PLBA
Skin prick test data from two published immunotherapy trials were used. In a D. farinae trial we used duplicate tests with three fixed ten-fold concentrations and in a P. judaica trial three tenfold individually chosen allergen concentrations causing wheals of similar size to that of histamine di hydrochloride 10 mg/mL, tenfold lower and tenfold higher concentration. Evaluation of the δSPT by PLBA, and two simple methods were correlated. In the D. farinae trial δ SPT was compared to the change of conjunctival threshold concentration
The δSPT as measured by both the simple methods gave similar results to that of PLBA (p<0.001). The δSPT was around 30-fold, i.e., about 3% of the pre-treatment reactivity. The δS PT correlated with the δ CPT threshold concentration.
Estimation of the δ SPT during therapy expressed as change in concentration using simple methods based on the slope of the drra correlated well to changes by PLBA and CPT and should therefore be used both in clinical research and in practice.

Medial contact

Alex john
Editorial assistant
Immunotherapy Open Accress